These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28490209)

  • 1. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.
    Schiavi MC; Zullo MA; Faiano P; D'Oria O; Prata G; Colagiovanni V; Giannini A; Di Tucci C; Perniola G; Di Donato V; Monti M; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2017 Dec; 33(12):942-945. PubMed ID: 28490209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?
    Schiavi MC; Sciuga V; Giannini A; Vena F; D'oria O; Prata G; Di Tucci C; Savone D; Aleksa N; Capone C; Di Mascio D; Meggiorini ML; Monti M; Zullo MA; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2018 Aug; 34(8):666-669. PubMed ID: 29463148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential effectiveness of Ospemifene on Detrusor Overactivity in patients with vaginal atrophy.
    Novara L; Sgro LG; Mancarella M; Capece R; Canale E; Biglia N
    Maturitas; 2020 Aug; 138():58-61. PubMed ID: 32631589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy.
    Russo E; Misasi G; Montt-Guevara MM; Giannini A; Simoncini T
    Climacteric; 2023 Jun; 26(3):284-288. PubMed ID: 36912363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A medical device containing purified bovine colostrum (Monurelle Biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: Retrospective analysis of urinary symptoms, sexual function, and quality of life.
    Schiavi MC; Di Tucci C; Colagiovanni V; Faiano P; Giannini A; D'Oria O; Prata G; Perniola G; Monti M; Zullo MA; Muzii L; Benedetti Panici P
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O11-O15. PubMed ID: 29057583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgery.
    Schiavi MC; D'Oria O; Aleksa N; Vena F; Prata G; Di Tucci C; Savone D; Sciuga V; Giannini A; Meggiorini ML; Monti M; Zullo MA; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2019 Feb; 35(2):155-159. PubMed ID: 30324854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study.
    Matarazzo MG; Sarpietro G; Fiorito D; Di Pasqua S; Ingrassano S; Panella MM; Cianci A; Caruso S
    Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():67-71. PubMed ID: 34167036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
    Dokmeci F; Cetinkaya SE; Seval MM; Dai O
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?
    Matarazzo MG; Caruso S; Giunta G; Valenti G; Sarpietro G; Cianci A
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():75-79. PubMed ID: 29367168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
    Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
    Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urogynecological survey in a group of Italian women treated for overactive bladder: Symptoms and quality of life analysis during the Covid-19 period.
    Schiavi MC; Zullo MA; Luffarelli P; Di Pinto A; Oliva C; Palazzetti P
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):674-678. PubMed ID: 34247805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
    Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
    Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results.
    Perino A; Cucinella G; Gugliotta G; Saitta S; Polito S; Adile B; Marci R; Calagna G
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2491-7. PubMed ID: 27383297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaginal health, endometrial thickness and changes in bone markers in postmenopausal women after 6 months of treatment with ospemifene in real clinical practice.
    Pingarrón C; Lafuente P; Poyo Torcal S; López Verdú H; Martínez García MS; Palacios S
    Gynecol Endocrinol; 2022 Jan; 38(1):78-82. PubMed ID: 34463164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.